<p>Rhythm Pharmaceuticals（納斯達克代碼：RYTM - 獲取免費報告）在週四發佈的研究報告中，Needham
&amp; Company LLC 將其目標價格從 120.00 美元上調至 145.00 美元，Benzinga 報道。該公司目前對該股票給予 “買入” 評級。Needham
&amp; Company LLC 的價格目標意味着該股票當前價格有 21.35% 的潛在上漲空間。</p>
<ul>
<li>7 只將推動減肥藥市場的股票</li>
</ul>
<p>其他幾位股票研究分析師也對 RYTM 發表了看法。JMP Securities 將 Rhythm Pharmaceuticals 的股票目標價格從 135.00 美元上調至 142.00 美元，並在 9 月 25 日的研究報告中給予該股票 “市場表現優於大盤” 的評級。華爾街 Zen 在 11 月 8 日的研究報告中將 Rhythm Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 10 月 8 日的報告中重申了對 Rhythm Pharmaceuticals 的 “賣出（d-）” 評級。摩根士丹利在 10 月 16 日的研究報告中將 Rhythm Pharmaceuticals 的目標價格從 122.00 美元上調至 129.00 美元，並給予該股票 “增持” 評級。最後，HC Wainwright 在 9 月 29 日的報告中將 Rhythm Pharmaceuticals 的目標價格從 100.00 美元上調至 110.00 美元，並給予該公司 “買入” 評級。一位研究分析師給予該股票 “強烈買入” 評級，十三位分析師給予 “買入” 評級，一位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價格為 116.50 美元。</p>
<p>獲取 <strong>Rhythm Pharmaceuticals</strong> 的提醒：</p>
<p><strong>閲讀我們關於 RYTM 的最新研究報告</strong></p>
<h2>Rhythm Pharmaceuticals 股價上漲 14.0%</h2>
<ul>
<li>2 家生物科技公司推出有前景的減肥藥</li>
</ul>
<p>週四交易時段，RYTM 股票上漲 14.72 美元，達到 119.49 美元。該公司的股票交易量為 2,410,748 股，而其平均交易量為 666,357 股。該公司的 50 日移動平均線為 104.61 美元，200 日移動平均線為 91.49 美元。該股票的市值為 79.7 億美元，市盈率為-38.55，貝塔值為 1.96。Rhythm Pharmaceuticals 的 12 個月低點為 45.90 美元，12 個月高點為 122.20 美元。</p>
<p>Rhythm Pharmaceuticals（納斯達克代碼：RYTM - 獲取免費報告）最近於 11 月 4 日發佈了季度財報。該公司報告每股收益（EPS）為-0.82 美元，低於共識預期的-0.72 美元，差距為 0.10 美元。該公司季度收入為 5130 萬美元，而分析師預期為 5071 萬美元。Rhythm Pharmaceuticals 的股本回報率為-433.21%，淨利潤率為-110.32%。平均而言，股票分析師預計 Rhythm Pharmaceuticals 在當前財政年度將發佈-4.32 的每股收益。</p>
<h2>Rhythm Pharmaceuticals 的內部交易</h2>
<p>在 Rhythm Pharmaceuticals 的其他消息中，內部人士 Joseph Shulman 於 10 月 30 日星期四出售了 9,748 股該公司的股票。該股票以 115.24 美元的平均價格出售，總價值為 1,123,359.52 美元。交易完成後，內部人士在公司中持有 8,509 股，價值 980,577.16 美元。此交易代表其持股比例減少了 53.39%。該出售在向證券交易委員會提交的文件中披露，文件可通過此超鏈接獲取。在過去的一個季度中，內部人士共出售了價值 3,064,490 美元的 27,000 股公司股票。內部人士持有公司 6.10% 的股份。</p>
<h2>機構資金流入和流出</h2>
<p>幾家機構投資者最近調整了對該股票的持有。Smartleaf Asset Management LLC 在第三季度將其在 Rhythm Pharmaceuticals 的股份增加了 97.2%。Smartleaf Asset Management LLC 目前持有 286 股該公司的股票，價值 29,000 美元，此前在上個季度購買了 141 股。BI Asset Management Fondsmaeglerselskab A S 在第一季度購買了 Rhythm Pharmaceuticals 的新股份，價值約 34,000 美元。Farther Finance Advisors LLC 在第三季度將其在 Rhythm Pharmaceuticals 的股份增加了 1,110.3%。Farther Finance Advisors LLC 目前持有 351 股該公司的股票，價值 35,000 美元，此前在此期間購買了 322 股。Optiver Holding B.V.在第三季度將其在 Rhythm Pharmaceuticals 的持股增加了 65.2%。Optiver Holding B.V.目前持有 365 股該公司的股票，價值 37,000 美元，此前在上個季度增加了 144 股。最後，Osaic Holdings Inc.在第二季度將其在 Rhythm Pharmaceuticals 的持股增加了 65.9%。Osaic Holdings Inc.目前持有 979 股該公司的股票，價值 62,000 美元，此前在上個季度增加了 389 股。</p>
<h2>Rhythm Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Rhythm Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於罕見的神經內分泌疾病。該公司的主要產品候選藥物是 IMCIVREE（setmelanotide），用於治療促黑激素前體（POMC）、前蛋白轉化酶亞型 1、瘦素受體（LEPR）缺乏症肥胖以及巴爾代 - 比德爾綜合症和阿爾斯特綜合症。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Rhythm Pharmaceuticals</li>
<li>如何使用 MarketBeat 股息計算器</li>
<li>AST SpaceMobile 為下週的 BlueBird 6 發射做好準備</li>
<li>複利是如何計算的？</li>
<li>人工智能與量子計算的下一個贏家：2026 年值得關注的 3 只小盤股</li>
<li>什麼是 SEC 文件？</li>
<li>三隻冬季股票，具有良好的增長機會</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Rhythm Pharmaceuticals 嗎？</h2>
<p>在考慮 Rhythm Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rhythm Pharmaceuticals 並不在名單上。</p>
<p>雖然 Rhythm Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RYTM

<p>Needham & Company LLC 將 Rhythm Pharmaceuticals 的目標股價從 120 美元上調至 145 美元，維持 “買入” 評級，表明潛在上漲幅度為 21.35%。其他分析師的評級各不相同，普遍共識為 “適度買入”，平均目標股價為 116.50 美元。該股票最近上漲了 14%，達到 119.49 美元，市值為 79.7 億美元</p>

<p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) had its target price upped by investment analysts at Needham &amp; Company LLC from $120.00 to $145.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Needham &amp; Company LLC's price objective would indicate a potential upside of 21.35% from the stock's current price.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（納斯達克代碼：RYTM - 獲取免費報告）在週四發佈的研究報告中，Needham
&amp; Company LLC 將其目標價格從 120.00 美元上調至 145.00 美元，Benzinga 報道。該公司目前對該股票給予 “買入” 評級。Needham
&amp; Company LLC 的價格目標意味着該股票當前價格有 21.35% 的潛在上漲空間。</p>
</div><ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><ul>
<li>7 只將推動減肥藥市場的股票</li>
</ul>
</div><p>Several other equities research analysts have also weighed in on RYTM. JMP Securities increased their price objective on shares of Rhythm Pharmaceuticals from $135.00 to $142.00 and gave the stock a &#34;market outperform&#34; rating in a research note on Thursday, September 25th. Wall Street Zen lowered shares of Rhythm Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Saturday, November 8th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Rhythm Pharmaceuticals in a report on Wednesday, October 8th. Morgan Stanley boosted their price objective on Rhythm Pharmaceuticals from $122.00 to $129.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, October 16th. Finally, HC Wainwright raised their price target on Rhythm Pharmaceuticals from $100.00 to $110.00 and gave the company a &#34;buy&#34; rating in a report on Monday, September 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $116.50.</p>
<div class="lb-trans"><p>其他幾位股票研究分析師也對 RYTM 發表了看法。JMP Securities 將 Rhythm Pharmaceuticals 的股票目標價格從 135.00 美元上調至 142.00 美元，並在 9 月 25 日的研究報告中給予該股票 “市場表現優於大盤” 的評級。華爾街 Zen 在 11 月 8 日的研究報告中將 Rhythm Pharmaceuticals 的股票評級從 “持有” 下調至 “賣出”。Weiss Ratings 在 10 月 8 日的報告中重申了對 Rhythm Pharmaceuticals 的 “賣出（d-）” 評級。摩根士丹利在 10 月 16 日的研究報告中將 Rhythm Pharmaceuticals 的目標價格從 122.00 美元上調至 129.00 美元，並給予該股票 “增持” 評級。最後，HC Wainwright 在 9 月 29 日的報告中將 Rhythm Pharmaceuticals 的目標價格從 100.00 美元上調至 110.00 美元，並給予該公司 “買入” 評級。一位研究分析師給予該股票 “強烈買入” 評級，十三位分析師給予 “買入” 評級，一位分析師給予 “持有” 評級，一位分析師給予 “賣出” 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 “適度買入”，平均目標價格為 116.50 美元。</p>
</div><p>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rhythm Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Research Report on RYTM</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 RYTM 的最新研究報告</strong></p>
</div><h2>Rhythm Pharmaceuticals Trading Up 14.0%</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 股價上漲 14.0%</h2>
</div><ul>
<li>2 biotechs with promising weight-loss drugs coming</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家生物科技公司推出有前景的減肥藥</li>
</ul>
</div><p>Shares of RYTM stock traded up $14.72 during trading hours on Thursday, hitting $119.49. The company's stock had a trading volume of 2,410,748 shares, compared to its average volume of 666,357. The business has a fifty day moving average of $104.61 and a 200-day moving average of $91.49. The stock has a market cap of $7.97 billion, a price-to-earnings ratio of -38.55 and a beta of 1.96. Rhythm Pharmaceuticals has a twelve month low of $45.90 and a twelve month high of $122.20.</p>
<div class="lb-trans"><p>週四交易時段，RYTM 股票上漲 14.72 美元，達到 119.49 美元。該公司的股票交易量為 2,410,748 股，而其平均交易量為 666,357 股。該公司的 50 日移動平均線為 104.61 美元，200 日移動平均線為 91.49 美元。該股票的市值為 79.7 億美元，市盈率為-38.55，貝塔值為 1.96。Rhythm Pharmaceuticals 的 12 個月低點為 45.90 美元，12 個月高點為 122.20 美元。</p>
</div><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.10). The firm had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.71 million. Rhythm Pharmaceuticals had a negative return on equity of 433.21% and a negative net margin of 110.32%. On average, equities analysts expect that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（納斯達克代碼：RYTM - 獲取免費報告）最近於 11 月 4 日發佈了季度財報。該公司報告每股收益（EPS）為-0.82 美元，低於共識預期的-0.72 美元，差距為 0.10 美元。該公司季度收入為 5130 萬美元，而分析師預期為 5071 萬美元。Rhythm Pharmaceuticals 的股本回報率為-433.21%，淨利潤率為-110.32%。平均而言，股票分析師預計 Rhythm Pharmaceuticals 在當前財政年度將發佈-4.32 的每股收益。</p>
</div><h2>Insider Transactions at Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 的內部交易</h2>
</div><p>In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 9,748 shares of the firm's stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $115.24, for a total value of $1,123,359.52. Following the completion of the transaction, the insider owned 8,509 shares in the company, valued at $980,577.16. This trade represents a 53.39% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 27,000 shares of company stock worth $3,064,490. Insiders own 6.10% of the company's stock.</p>
<div class="lb-trans"><p>在 Rhythm Pharmaceuticals 的其他消息中，內部人士 Joseph Shulman 於 10 月 30 日星期四出售了 9,748 股該公司的股票。該股票以 115.24 美元的平均價格出售，總價值為 1,123,359.52 美元。交易完成後，內部人士在公司中持有 8,509 股，價值 980,577.16 美元。此交易代表其持股比例減少了 53.39%。該出售在向證券交易委員會提交的文件中披露，文件可通過此超鏈接獲取。在過去的一個季度中，內部人士共出售了價值 3,064,490 美元的 27,000 股公司股票。內部人士持有公司 6.10% 的股份。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Several institutional investors have recently modified their holdings of the stock. Smartleaf Asset Management LLC grew its stake in shares of Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company's stock worth $29,000 after purchasing an additional 141 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Rhythm Pharmaceuticals in the 1st quarter worth approximately $34,000. Farther Finance Advisors LLC increased its stake in shares of Rhythm Pharmaceuticals by 1,110.3% during the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company's stock valued at $35,000 after buying an additional 322 shares during the period. Optiver Holding B.V. raised its holdings in shares of Rhythm Pharmaceuticals by 65.2% during the third quarter. Optiver Holding B.V. now owns 365 shares of the company's stock valued at $37,000 after acquiring an additional 144 shares in the last quarter. Finally, Osaic Holdings Inc. raised its holdings in shares of Rhythm Pharmaceuticals by 65.9% during the second quarter. Osaic Holdings Inc. now owns 979 shares of the company's stock valued at $62,000 after acquiring an additional 389 shares in the last quarter.</p>
<div class="lb-trans"><p>幾家機構投資者最近調整了對該股票的持有。Smartleaf Asset Management LLC 在第三季度將其在 Rhythm Pharmaceuticals 的股份增加了 97.2%。Smartleaf Asset Management LLC 目前持有 286 股該公司的股票，價值 29,000 美元，此前在上個季度購買了 141 股。BI Asset Management Fondsmaeglerselskab A S 在第一季度購買了 Rhythm Pharmaceuticals 的新股份，價值約 34,000 美元。Farther Finance Advisors LLC 在第三季度將其在 Rhythm Pharmaceuticals 的股份增加了 1,110.3%。Farther Finance Advisors LLC 目前持有 351 股該公司的股票，價值 35,000 美元，此前在此期間購買了 322 股。Optiver Holding B.V.在第三季度將其在 Rhythm Pharmaceuticals 的持股增加了 65.2%。Optiver Holding B.V.目前持有 365 股該公司的股票，價值 37,000 美元，此前在上個季度增加了 144 股。最後，Osaic Holdings Inc.在第二季度將其在 Rhythm Pharmaceuticals 的持股增加了 65.9%。Osaic Holdings Inc.目前持有 979 股該公司的股票，價值 62,000 美元，此前在上個季度增加了 389 股。</p>
</div><h2>Rhythm Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals, Inc.是一家商業階段的生物製藥公司，專注於罕見的神經內分泌疾病。該公司的主要產品候選藥物是 IMCIVREE（setmelanotide），用於治療促黑激素前體（POMC）、前蛋白轉化酶亞型 1、瘦素受體（LEPR）缺乏症肥胖以及巴爾代 - 比德爾綜合症和阿爾斯特綜合症。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Rhythm Pharmaceuticals</li>
<li>How to Use the MarketBeat Dividend Calculator</li>
<li>AST SpaceMobile Gears Up for Its BlueBird 6 Launch Next Week</li>
<li>How is Compound Interest Calculated?</li>
<li>AI &amp; Quantum's Next Big Winners: 3 Small-Cap Stocks to Watch in 2026</li>
<li>What is a SEC Filing?</li>
<li>Top 3 Winter Stocks With Solid Growth Opportunities</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Rhythm Pharmaceuticals</li>
<li>如何使用 MarketBeat 股息計算器</li>
<li>AST SpaceMobile 為下週的 BlueBird 6 發射做好準備</li>
<li>複利是如何計算的？</li>
<li>人工智能與量子計算的下一個贏家：2026 年值得關注的 3 只小盤股</li>
<li>什麼是 SEC 文件？</li>
<li>三隻冬季股票，具有良好的增長機會</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RYTM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Rhythm Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rhythm Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rhythm Pharmaceuticals 並不在名單上。</p>
</div><p>While Rhythm Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rhythm Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Needham & Company LLC 的分析師表示，預計 Rhythm Pharmaceuticals（NASDAQ:RYTM）的股價將會上漲